3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Triple Negative Breast Neoplasms
5
Breast Neoplasms
5
Carcinoma, Non-Small-Cell Lung
4
Carcinoma, Transitional Cell
3
Neoplasm Metastasis
2
Urinary Bladder Neoplasms
1
Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma
1
Prostatic Neoplasms
1
Muscle Invasive Bladder Urothelial Carcinoma
1
Lung Neoplasms
1
Lung Diseases
1
Locally Advanced or Metastatic Unresectable Urothelial Cancer
1
Liver Failure
1
HRD Cancer
1
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
1
Drug-Related Side Effects and Adverse Reactions
1
Brain Neoplasms
1
Advanced Solid Tumors
1
Interventions
Paclitaxel
16
pembrolizumab
15
Carboplatin
13
Specimen Handling
9
Magnetic Resonance Spectroscopy
8
Biopsy
7
Bevacizumab
7
Fulvestrant
6
olaparib
5
Taxes
5
Megestrol Acetate
5
Doxorubicin
5
Cisplatin
5
trastuzumab deruxtecan
4
dostarlimab
4
Nivolumab
4
Gemcitabine
4
palbociclib
3
durvalumab
3
Progestins
3
Oxaliplatin
3
Medroxyprogesterone Acetate
3
Leucovorin
3
Letrozole
3
Immunoglobulin G
3
Fluorouracil
3
Docetaxel
3
Disulfides
3
ribociclib
2
pertuzumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Endometrial Neoplasms
×
sacituzumab govitecan
×
30 days
×
Clear all
No trials found.